Literature DB >> 5646098

National survey of value of plasma standards for anticoagulant therapy.

L Poller, J M Thomson.   

Abstract

Mesh:

Substances:

Year:  1968        PMID: 5646098      PMCID: PMC1985753          DOI: 10.1136/bmj.2.5597.88

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  4 in total

1.  STANDARDIZATION OF ANTICOAGULANT TREATMENT: THE MANCHESTER REGIONAL THROMBOPLASTIN SCHEME.

Authors:  L POLLER
Journal:  Br Med J       Date:  1964-08-29

2.  A national standard for anticoagulant therapy. The Manchester comparative reagent.

Authors:  L Poller
Journal:  Lancet       Date:  1967-03-04       Impact factor: 79.321

3.  1963 prothrombin time test survey, College of American Pathologists, Standards Committee, Subcommittee on Coagulation.

Authors:  J B Miale; D J Lafond
Journal:  Am J Clin Pathol       Date:  1967-01       Impact factor: 2.493

4.  Standardization of the one-stage prothrombin time for the control of anticoagulant therapy.

Authors:  R Biggs; K W Denson
Journal:  Br Med J       Date:  1967-01-14
  4 in total
  4 in total

Review 1.  Etiology of breast cancer. II. Epidemiologic aspects.

Authors:  D V Vakil; R W Morgan
Journal:  Can Med Assoc J       Date:  1973-08-04       Impact factor: 8.262

2.  [Activity of reagents for thromboplastin-time determination (Quick test) of various manufacturers in changing concentrations of several blood coagulation factors].

Authors:  R Averdunk; J S Braun
Journal:  Blut       Date:  1972-05

3.  Identification of a congenital defect of factor VII in a colony of beagle dogs: the clinical use of the plasma.

Authors:  L Poller; J M Thomson; C H Sear; W Thomas
Journal:  J Clin Pathol       Date:  1971-10       Impact factor: 3.411

4.  The "therapeutic range" of the one-stage prothrombin time in the control of anticoagulant therapy: the effect of different thromboplastin preparations.

Authors:  E L Bailey; T A Harper; P H Pinkerton
Journal:  Can Med Assoc J       Date:  1971-11-20       Impact factor: 8.262

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.